methyl 2'-(dimethoxymethyl)-2-nitrobiphenyl-4-carboxylate | 1047622-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: methyl 2'-(dimethoxymethyl)-2-nitrobiphenyl-4-carboxylate
• 英文别名: Methyl 4-[2-(dimethoxymethyl)phenyl]-3-nitrobenzoate
• CAS: 1047622-09-2
• 化学式: C₁₇H₁₇NO₆
• 分子量: 331.325
• InChiKey: IODOLVVSJASUJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甲醇 、 methyl 2'-formyl-2-nitrobiphenyl-4-carboxylate 生成 methyl 2'-(dimethoxymethyl)-2-nitrobiphenyl-4-carboxylate
  参考文献：
  名称：

  EP2119704

  摘要：

  公开号：

文献信息

• ACYLGUANIDINE DERIVATIVE
  申请人：Kinoyama Isao

  公开号：US20100324017A1

  公开（公告）日：2010-12-23

  An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT 5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at the center and guanidine are bonded via a carbonyl group has a potent 5-HT 5A receptor modulating action and an excellent pharmacological action based thereon, and thus, it was found that the compound can be an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, particularly for memory-related functional disorders such as cognitive impairments including dementia and schizophrenia, thereby completing the present invention.

  本发明的目的是提供一种基于5-HT5A受体调节作用的新型优良的治疗或预防痴呆症、精神分裂症等药剂。经证实，一种以三环杂环在中心具有吡咯环，并通过羰基结合了胍的结构特征化合物具有强效的5-HT5A受体调节作用和基于此的优良药理作用，因此，发现该化合物可以成为治疗或预防痴呆症、精神分裂症、躁郁症或注意力缺陷多动障碍等的优良药剂，特别是对于认知障碍包括痴呆症和精神分裂症等的记忆相关功能障碍，从而完成了本发明。